The U.S. FDA approved the combination of lenvatinib and pembrolizumab to treat adult patients with renal cell carcinoma, the most common form of kidney cancer. The U.S. Food and Drug Administration (FDA) approved the...
The father of a child diagnosed with brain cancer calls for better financial support for families, and more news of the week from Cancer Today.
Remetinostat, a topical therapy that works by inhibiting the expression of cancer-promoting genes, could reduce the need for surgical removal of many subtypes of basal cell carcinoma lesions.
This year marks the 10th anniversary of Cancer Discovery, a journal of the AACR. To celebrate the anniversary, Cancer Discovery published a special anniversary issue, featured spotlights on groundbreaking articles on its website, and held the Cancer Discovery 10th Anniversary Symposium in June. A recent blog post discussed these commemorations and captured remarks delivered at the symposium by the AACR and Cancer Discovery leadership. Cancer...
Healthy lifestyle habits can reduce the risk of cancer, and other cancer research news of the week selected by the staff of Cancer Today magazine.
Exercise, healthful diet, no smoking or drinking are correlated with lower risk for cancer even in people with higher risk based on their genetic makeup.
The U.S. FDA approved the immune checkpoint inhibitor pembrolizumab combined with chemotherapy to treat certain breast cancer patients before surgery. The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic pembrolizumab for patients with...
Two studies on access to opioids identify disturbing patterns, and more news of the week from Cancer Today.
The U.S. FDA approved a combination of a molecularly targeted therapeutic and an immunotherapeutic to treat certain patients with uterine cancer. The U.S. Food and Drug Administration (FDA) approved the combination of the immunotherapeutic...
Recently published clinical trial results suggest that combining an investigational antibody therapy with chemotherapy may be an effective strategy for patients with relapsed disease.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More